TY - JOUR T1 - An overview of immune checkpoint inhibitors in breast cancer A1 - Miglietta, Federica A1 - Cona, Maria Silvia A1 - Dieci, Maria Vittoria A1 - Guarneri, Valentina A1 - La Verde, Nicla Y1 - 2020/// KW - early breast cancer KW - immune checkpoint inhibitors KW - immunotherapy KW - metastatic breast cancer JF - Exploration of Targeted Anti-tumor Therapy VL - 1 SP - 452 EP - 472 DO - 10.37349/etat.2020.00029 N2 - Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting. ER -